About mdxhealth sa - MDXH
MDxHealth SA is a commercial-stage precision diagnostics company, which engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. It operates through the following geographical segments: United States of America, Europe and Rest of the World. The firm offers ConfirmMDx, SelectMDx, AssureMDx, InformMDx, SelectMDx, and MonitorMDx. The company was founded by Herman Spolders and Philip S. Devine on January 10, 2003 and is headquartered in Herstal, Belgium.
MDXH At a Glance
MDxHealth SA
CAP Business Center
Herstal, Walloon Region 4040
| Phone | 32-4-257-70-21 | Revenue | 107.88M | |
| Industry | Medical Specialties | Net Income | -33,519,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 19.796% | |
| Fiscal Year-end | 12 / 2026 | Employees | 364 | |
| View SEC Filings |
MDXH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.653 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -38.098 |
| Enterprise Value to Sales | 2.187 |
| Total Debt to Enterprise Value | 0.367 |
MDXH Efficiency
| Revenue/Employee | 296,359.89 |
| Income Per Employee | -92,085.165 |
| Receivables Turnover | 7.324 |
| Total Asset Turnover | 0.707 |
MDXH Liquidity
| Current Ratio | 1.078 |
| Quick Ratio | 0.942 |
| Cash Ratio | 0.586 |
MDXH Profitability
| Gross Margin | 59.737 |
| Operating Margin | -14.277 |
| Pretax Margin | -32.794 |
| Net Margin | -31.072 |
| Return on Assets | -21.959 |
| Return on Equity | -2,440.408 |
| Return on Total Capital | -44.986 |
| Return on Invested Capital | -45.969 |
MDXH Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 116.231 |
| Total Debt to Total Assets | 58.535 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 113.684 |